NVS
Novartis Pharmaceuticals
Phase 3
Estimated
LOU064 (blinded)
Chronic Spontaneous Urticaria
T-minus 3 days
Nov 6, 2026
ClinicalTrials.gov
verified 4mo ago
Countdown card β